Diabetes, Healthy
Conditions
Brief summary
This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.
Interventions
DRUGsemaglutide
Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Good general health * Body mass index (BMI) of 18.5-30.0 kg/m\^2 (both inclusive)
Exclusion criteria
* Males who are not willing to use two acceptable forms of highly effective contraception * Participation in another clinical trial within 90 days * Any chronic disorder or severe disease * Use of GLP-1 (glucagon-like peptide-1) agonists within 3 months preceding dosing * Subjects who are smokers * Subjects who have donated any blood or plasma in the past month or in excess of 500 mL within the 12 weeks preceding screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE) | Assessed 0-4 hours post dose |
Secondary
| Measure | Time frame |
|---|---|
| Area under the NN9924 concentration curve | From time 0-24 hours |
| Anatomical location of initial tablet erosion (ITE) | Assessed 0-4 hours post dose |
| Time to ITE | Assessed 0-4 hours post dose |
| Time to CTE | Assessed 0-4 hours post dose |
Countries
United Kingdom
Outcome results
None listed